Biomea Fusion Announced Saturday Near Doubling The Percentage Of Patients With Durable HbA1c Reduction In the 200 Mg Dose Cohorts
Biomea Fusion Announced Saturday Near Doubling The Percentage Of Patients With Durable HbA1c Reduction In the 200 Mg Dose Cohorts
Biomea Fusion周六宣布，在200毫克剂量队列中，持续减少Hba1c的患者比例几乎翻了一番
Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseasesannounced top line data of the 200 mg dose cohorts from the ongoing Phase II clinical study (COVALENT-111) which will be presented in more detail at the International Conference on Advanced Technologies and Treatments of Diabetes (ATTD) in March 2024.
Biomea Fusion, Inc.（“Biomea”）（纳斯达克股票代码：BMEA）（纳斯达克股票代码：BMEA）是一家临床阶段的生物制药公司，致力于发现和开发用于治疗和改善基因定义的癌症和代谢性疾病患者的生活的新型共价小分子，公布了正在进行的二期临床研究（COVALENT-111）中200毫克剂量的顶线数据，该数据将在国际高级会议上更详细地公布《糖尿病技术和治疗》（ATTD）将于2024年3月发布。
- At Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients to approximately 40% with durable HbA1c reduction of 1% or more as compared to the 100 mg cohorts which reported earlier as 20%.
- To date, the dose escalation portion has shown after only 4 weeks of dosing with BMF-219 that patients across all dosing cohorts have consistently experienced generally meaningful HbA1c reductions and no serious adverse events or study discontinuations.
- 在第 26 周，即最后一剂 BMF-219 剂量 22 周后，200 毫克队列将患者的百分比提高到大约 40%，HbA1c 持续降低 1% 或以上，而之前报告的 100 毫克队列为 20%。
- 迄今为止，剂量递增部分显示，在给药 BMF-219 仅四周后，所有给药队列的患者都经历了总体上有意义的 HbA1c 降低，没有严重的不良事件或研究中止。